PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-299.87%
Negative net income growth while CRON.TO stands at 211.37%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
38.60%
Less D&A growth vs. CRON.TO's 136.27%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
-743.87%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
496.12%
SBC growth well above CRON.TO's 54.80%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-210.10%
Negative yoy working capital usage while CRON.TO is 82.84%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
135.91%
AR growth well above CRON.TO's 89.23%. Michael Burry would fear inflated sales or less stringent credit controls vs. competitor.
-67.21%
Both reduce yoy inventory, with CRON.TO at -105.99%. Martin Whitman would find a widespread caution or cyclical demand drop in the niche.
-143.11%
Negative yoy AP while CRON.TO is 288.82%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-64.54%
Negative yoy usage while CRON.TO is 46.21%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
217.83%
Some yoy increase while CRON.TO is negative at -204.31%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-1249.62%
Negative yoy CFO while CRON.TO is 54.35%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
7.24%
Some CapEx rise while CRON.TO is negative at -46.50%. John Neff would see competitor possibly building capacity while we hold back expansions.
-878.89%
Negative yoy acquisition while CRON.TO stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
77.18%
Purchases well above CRON.TO's 99.98%. Michael Burry would see major cash outflow into securities vs. competitor’s approach, risking near-term FCF.
349.80%
Liquidation growth of 349.80% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-2950.17%
Both yoy lines negative, with CRON.TO at -22.22%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
75.41%
Investing outflow well above CRON.TO's 84.93%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-4.64%
Both yoy lines negative, with CRON.TO at -81.09%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
144.58%
Issuance growth of 144.58% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.